Sotera Health Posts Strong Q1 2026 Earnings, Reaffirms Full-Year Outlook
Sotera Health, a leading provider of mission-critical regulated services to the healthcare industry, reported strong first-quarter 2026 earnings and reaffirmed its full-year outlook during its quarterly conference call on May 5.
Chairman and CEO Michael B. Petras, Jr., highlighted the company's impressive revenue growth, with Sterigenics delivering 6.1% constant currency revenue growth and Nordion growing constant currency revenue by a significant 25.8%. Nelson Labs results were in line with expectations, while the overall company reported 6.5% constant currency revenue growth and 6.9% constant currency Adjusted EBITDA growth.
"We're pleased to report a strong start to the year," Petras said. "Our commitment to customers is a core company value, and we've delivered substantial improvements in our customer satisfaction scores across both Sterigenics and Nelson Labs."
The company's business model has demonstrated resilience over time, delivering consistent revenue growth for the past two decades across multiple economic cycles. Sotera Health's mission-critical regulated services are deeply embedded in its customers' supply chains, with more than 70% of revenue supported by multi-year contracts.
"We sit in a unique position in the healthcare supply chain and take our mission of safeguarding global health very seriously," Petras emphasized. "Our business model has consistently delivered growth across multiple economic cycles."
Chief Financial Officer Jonathan M. Lyons provided detailed financial information, including GAAP and non-GAAP measures such as Adjusted EBITDA, Adjusted Net Income, and Adjusted Free Cash Flow. The company reaffirmed its full-year outlook for 2026, expecting total revenue to increase to a range of $1.23 billion-$1.25 billion, representing constant currency growth of 5%-6.5% versus 2025.
Sotera Health also announced the addition of Ken Krause and the departure of Constantine S. Mihas and Robert Canals from its board of directors. "We're excited to welcome Ken Krause to our board, whose leadership experience will be a valuable asset as we continue to grow," Petras said.
The company's strong Q1 2026 earnings and reaffirmed full-year outlook are expected to drive growth in the healthcare industry.
